Oligomerix
Dr. Dantzker is a general partner with Wheatley MedTech Partners L.P., and manages Wheatley Partner’s Life Science and Healthcare investments. He was President of North Shore-LIJ Health System (annual revenue over $3 billion); and co-founded the North Shore-LIJ Research Institute. He was Chair of the American Board of Internal Medicine and served senior appointments on the faculty at four medical schools. He is a member of the boards of five private and public companies and has served on numerous others in the past. Dr. Dantzker holds a B.A. in biology from NYU and received his M.D. from SUNY Buffalo School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.